1. Andersen, J. T., &Futtrup, T. B. (2020). Drugs in pregnancy. Adverse Drug Reaction Bulletin, 321(1), 1243–1246. doi:10.1097/fad.0000000000000047.

2. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 2015;105:140–156

3. McCallister JW. Asthma in pregnancy: management strategies. CurrOpinPulm Med 2013;19:13–17.

4. Giden K, Andersen JT, Torp-Pedersen AL, et al. Use of thyroid hormones in relation to pregnancy: a Danish nationwide cohort study. ActaObstetGynecolScand 2015;94: 591–597.

5. Thomseth V, Cejvanovic V, Jimenez-Solem E, et al. Exposure to topical chloramphenicol during pregnancy and the risk of congenital malformations: a Danish nationwide cohort study. ActaOphthalmol 2015;93: 6513.

6. Andersen J, Rasmussen J, Glintborg B, et al. Changes in antibiotic prescription in pregnancy are not explained by present guidelines. Pharmacoepidemiol. Drug Saf 2008; 17:S160.

7. Nordeng H. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J ClinPharmacol 2010;66:207–214.

8. Eck LK, Jensen TB, Mastrogiannis D, et al. Risk of adverse pregnancy outcome after paternal exposure to methotrexate within 90 days before pregnancy. ObstetGynecol 2017;129:707–714.

9. Khiali S, Gharekhani A, Entezari-Maleki T. Isotretinoin; A review on the Utilization Pattern in Pregnancy. Adv Pharm Bull 2018;8:377–382

10. Schardein JL. Chemically induced birth defects, third edition. Chapter one: principles of teratogenesis applicable to drug and chemical exposure. New York: Marcel Dekker, Inc; 2000.

11. Bergman TF, Andersen JT. Common pharmacological issues in pregnancy. RationelFarmakoterapi 2019;6:1–5.

12. Koren, G., Pastuszak, A., & Ito, S. (1998). Drugs in Pregnancy. New England Journal of Medicine, 338(16), 1128–1137. doi:10.1056/nejm199804163381607.

13. Loebstein R, Lalkin A, Koren G. Pregnancy induced pharmacokinetic changes and their clinical relevance. ClinPharmacokinet 1997;33:328-43.

14. Theis JGW. Acetylsalicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy: are they safe? Can Fam Physician 1996;42:2347-9.

15. Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf 2014;13:1569–1581.

16. Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation? Expert Opin Drug Saf 2016;15:367–382.

17. Eck LK, Jensen TB, Mastrogiannis D, et al. Risk of adverse pregnancy outcome after paternal exposure to methotrexate within 90 days before pregnancy. ObstetGynecol 2017;129:707–714

18. Haastrup MB. Analgetics in pregnancy.Ma˚nedsbladetRationelFarmakoterapi 2016;5:1–2.

19. Hyperemesis gravidarum - guideline - DSOG. 2013. http://gynobsguideline.dk/ sandbjerg/Hyperemesisgravidarum.pdf (16 Aug 2016).

20. Namazy JA, Schatz M. Management of asthma during pregnancy: optimizing outcomes and minimizing risk. SeminRespirCrit Care Med 2018;39:29–35.

21. Andersson NW, Poulsen HE, Andersen JT. Desloratadine use during pregnancy and risk of adverse fetal outcomes: a nationwide cohort study. J Allergy ClinImmunolPract 2020

22. Poulsen BK, Krag MØ. Treatment of allergy in pregnancy.Ma˚nedsbladetRationelFarmakoterapi 2017;6:3–4.

23. Ka¨llen BA, Olausson PO. Use of oral decongestants during pregnancy and delivery outcome. Am J ObstetGynecol 2006;194:480– 485

24. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J ClinEndocrinolMetab 2012;97:2543–2565.

25. Mølgaard-Nielsen D, Svanstr€om H, Melbye M, et al. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016;315:58–67.

26. Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013;369:830–839.

27. Bergman TF, Andersen JT. Common pharmacological issues in pregnancy. RationelFarmakoterapi 2019;6:1–5.

28. Larsen ER, Damkier P, Pedersen LH, et al., Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding.ActaPsychiatrScandSuppl 2015:1–28.

29. Cuomo A, Maina G, Neal SM, et al. Using sertraline in postpartum and breastfeeding: balancing risks and benefits. Expert Opin Drug Saf 2018;17:719–725

30. Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:. e001148.

31. Pasternak B, Hviid A. Use of protonpump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010;363:2114– 2123.

32. Vazquez JC. Constipation, haemorrhoids, and heartburn in pregnancy. BMJ ClinEvid 2008;2008:1411

33. Body C, Christie JA. gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. GastroenterolClin North Am 2016;45:267–283.